Drug Trial Radar · NCT05083923
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
Last checked: Nov 20, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
136
Actual
Start
Nov 18, 2021
Primary completion
Sep 11, 2024
Study completion Sep 11, 2024
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Oct 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to determine the safety and tolerability of DRF administered for up to 24 weeks in adult East Asian participants with RMS (Part 1) and to determine the safety and tolerability of DRF administered for up to 48 weeks in adult East Asian participants with RMS (Part 2). The secondary objective of this study is to evaluate the pharmacokinetic(s) (PK) of DRF metabolites (monomethyl fumarate \[MMF\] and 2-hydroxyethyl succinimide \[HES\]) following multiple doses of DRF in a subset of adult East Asian participants with RMS (Part 1).
Conditions
- Relapsing Forms of Multiple Sclerosis
Interventions
Diroximel fumarateDrug
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Baseline (Day 1) up to Week 24 (for prematurely discontinued participants, AEs were reported up to 2 weeks post discontinuation)
- Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory ParametersTime frame: Baseline (Day 1) to Week 24
- Part 1: Number of Participants With Abnormal Shift in 12-Lead Electrocardiogram (ECG) ValuesTime frame: Baseline (Day 1) to Week 24
- Part 1: Number of Participants With Clinically Relevant Abnormalities in Vital Sign ParametersTime frame: Baseline (Day 1) to Week 24
- Part 1: Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) EventsTime frame: Baseline (Day 1) to Week 24
- Parts 1 and 2: Number of Participants With TEAEs and TESAEsTime frame: From Day 1 up to the end of the study (up to Week 50)
- Part 2: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory ParametersTime frame: Baseline (Day 1) to Week 48
- Part 2: Number of Participants With Abnormal Shift in 12-Lead ECG ValuesTime frame: Baseline (Day 1) to Week 48
- Part 2: Number of Participants With Clinically Relevant Abnormalities in Vital Sign ParametersTime frame: Baseline (Day 1) to Week 48
- Part 2: Number of Participants With C-SSRS EventsTime frame: Baseline (Day 1) to Week 48
Locations
52 sites in 2 countries. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Hospital
Beijing, Beijing Municipality, China
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Lanzhou University Second Hospital
Lanzhou, Gansu, China
Dongguan People's Hospital
Dongguan, Guangdong, China
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Third Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Tangshan Gongren Hospital
Tangshan, Hebei, China
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Xiangya Hospital, Central South University
Changsha, Hu'nan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
Shengjing Hospital of China Medical University
Shengyang, Liaoning, China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia Hui, China
Tangdu Hospital, Fourth Military Medical University
Xi'an, Shan'xi, China
Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch
Shanghai, Shanghai Municipality, China
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Tianjin Medical University Affiliated General Hospital
Tianjin, Tianjin Municipality, China
First Affiliated Hospital of Kunming Medical University
Kunming, Yun'nan, China
Chiba University Hospital
Chiba, Chiba, Japan
Tokyo Womens Medical University Yachiyo Medical Center
Yachiyo, Chiba, Japan
Ehime University Hospital
Toon-shi, Ehime, Japan
Fukuoka University Hospital
Fukuoka, Fukuoka, Japan
Hospital of the University of Occupational and Environmental Health
Kitakyushu-shi, Fukuoka, Japan
Southern Tohoku Medical Clinic
Koriyama-shi, Fukushima, Japan
NHO Asahikawa Medical Center
Asahikawa-shi, Hokkaido, Japan
Obihiro Kosei Hospital
Obihiro, Hokkaido, Japan
NHO Hokkaido Medical Center
Sapporo, Hokkaido, Japan
University of Tsukuba Hospital
Tsukuba, Ibaraki, Japan
Iwate Medical University Uchimaru Medical Center
Morioka, Iwate, Japan
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.